Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Nov;21(11):1927-34.
doi: 10.1007/s00198-009-1149-x. Epub 2010 Jan 22.

Therapy of hypoparathyroidism with intact parathyroid hormone

M R Rubin  1 , J Sliney Jr, D J McMahon, S J Silverberg, J P Bilezikian
Affiliations
Clinical Trial

Therapy of hypoparathyroidism with intact parathyroid hormone

M R Rubin et al. Osteoporos Int. 2010 Nov.

Abstract

Hypoparathyroidism, a disorder characterized by low parathyroid hormone (PTH), is generally treated with oral calcium and vitamin D supplementation. We investigated the effects of PTH(1-84) treatment in 30 hypoparathyroid subjects for 24 months. PTH(1-84) treatment in hypoparathyroidism significantly reduced supplemental calcium and 1,25-dihydroxyvitamin D requirements without generally altering serum and urinary calcium levels.

Introduction: Hypoparathyroidism, a disorder characterized by low PTH, is associated with hypocalcemia, hypercalciuria, and increased bone mineral density (BMD). Conventional therapy with calcium and 1,25-dihydroxyvitamin D can maintain the serum calcium concentration, but doses are high, and control is variable. We investigated the effects of human PTH(1-84) treatment in hypoparathyroidism.

Methods: Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1-84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.

Results: Requirements for supplemental calcium decreased significantly (3,030±2,325 to 1,661±1,267 mg/day (mean±SD); p<0.05), as did requirements for supplemental 1,25-dihydroxyvitamin D (0.68±0.5 to 0.40±0.5 µg/day; p<0.05). Serum calcium levels and 24 h urinary calcium excretion were mostly unchanged at 24 months. BMD increased at the lumbar spine by 2.9±4% from baseline (p<0.05), while femoral neck BMD remained unchanged and distal one third radial BMD decreased by 2.4±4% (p<0.05).

Conclusion: PTH(1-84) treatment in hypoparathyroidism significantly reduces supplemental calcium and 1,25-dihydroxyvitamin D requirements without generally altering serum and urinary calcium levels.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Changes in turnover markers in dosing study in five patients. The five patients were assigned to either PTH(1–84) 100 μg every day (n=2), every other day (n=2), or every third day (n=1) for 6 months. a Change in bone formation markers. b Change in bone resorption markers
Fig. 2
Fig. 2
Changes in calcium and 1,25-dihydroxyvitamin D supplementation. Calcium requirements decreased at 3, 9, 12, 18, and 24 months from baseline while 1,25-dihydroxyvitamin D requirements decreased by 1 month. Data are mean±SD; *p<0.05 as compared to baseline
Fig. 3
Fig. 3
Changes in serum calcium, serum phosphate, and urinary calcium. Serum calcium increased at months 2 to 6 but was no different from baseline at 1, 9, 12, 18, and 24 months. Serum phosphate decreased into the normal range at month 3 and remained in the normal range through 24 months. The shaded area shows the normal ranges of serum calcium and phosphate. Urinary calcium increased at 3 months but, otherwise, did not change. The heavier and lighter dashed lines shows the upper limit of normal urinary calcium levels in men and women, respectively. Data are mean±SD; *p<0.05 as compared to baseline
Fig. 4
Fig. 4
Changes in bone mineral density. Lumbar spine bone mineral density (BMD) increased, while the femoral neck did not change and the distal one third radius BMD decreased. Data are mean±SD; *p< 0.05 as compared to baseline
See this image and copyright information in PMC

References

    1. Marx S. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863–1875. - PubMed
    1. Thakker R. Genetics of endocrine and metabolic disorders: parathyroid. Rev Endocr Metab Disord. 2004;5:37–51. - PubMed
    1. Rubin M, Levine M. Primer of metabolic bone diseases. American Society of Bone and Mineral Research; Washington: 2008. Hypoparathyroidism.
    1. Kao PC, van Heerden JA, Grant CS, Klee GG, Khosla S. Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc. 1992;67:637–645. - PubMed
    1. Michelangeli VP, Heyma P, Colman PG, Ebeling PR. Evaluation of a new, rapid and automated immunochemilumino-metric assay for the measurement of serum intact parathyroid hormone. Ann Clin Biochem. 1997;34(Pt 1):97–103. - PubMed

Publication types

MeSH terms